Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Disposition and metabolism of [14C]-galunisertib, a TGF-╬▓RI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics.

Cassidy KC, Gueorguieva I, Miles C, Rehmel J, Yi P, Ehlhardt WJ.

Xenobiotica. 2018 Apr;48(4):382-399. doi: 10.1080/00498254.2017.1323137. Epub 2017 May 16. Erratum in: Xenobiotica. 2018 Apr;48(4):x-xi.

PMID:
28436712
2.

Utilizing 19F NMR to investigate drug disposition early in drug discovery.

Hu H, Huang N, Yi P, Hui YH, Dally RD, Ehlhardt WJ, Kulanthaivel P.

Xenobiotica. 2015;45(12):1081-91. doi: 10.3109/00498254.2015.1040866. Epub 2015 May 6.

PMID:
25946562
3.

Dehydrogenation of indoline by cytochrome P450 enzymes: a novel "aromatase" process.

Sun H, Ehlhardt WJ, Kulanthaivel P, Lanza DL, Reilly CA, Yost GS.

J Pharmacol Exp Ther. 2007 Aug;322(2):843-51. Epub 2007 May 14.

4.

Selective metabolism of vincristine in vitro by CYP3A5.

Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD.

Drug Metab Dispos. 2006 Aug;34(8):1317-27. Epub 2006 May 5.

5.

Selective reduction of N-oxides to amines: application to drug metabolism.

Kulanthaivel P, Barbuch RJ, Davidson RS, Yi P, Rener GA, Mattiuz EL, Hadden CE, Goodwin LA, Ehlhardt WJ.

Drug Metab Dispos. 2004 Sep;32(9):966-72.

6.

Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells.

Reilly CA, Ehlhardt WJ, Jackson DA, Kulanthaivel P, Mutlib AE, Espina RJ, Moody DE, Crouch DJ, Yost GS.

Chem Res Toxicol. 2003 Mar;16(3):336-49.

PMID:
12641434
7.

Biosynthesis of drug glucuronides for use as authentic standards.

Soars MG, Mattiuz EL, Jackson DA, Kulanthaivel P, Ehlhardt WJ, Wrighton SA.

J Pharmacol Toxicol Methods. 2002 May-Jun;47(3):161-8.

PMID:
12628307
8.

Glutathione-dependent metabolism of the antitumor agent sulofenur. Evidence for the formation of p-chlorophenyl isocyanate as a reactive intermediate.

Jochheim CM, Davis MR, Baillie KM, Ehlhardt WJ, Baillie TA.

Chem Res Toxicol. 2002 Feb;15(2):240-8.

PMID:
11849051
9.

Binding of the epoxide cryptophycin analog, LY355703 to albumin and its effect on in vitro antiproliferative activity.

Schultz RM, Shih C, Wood PG, Harrison SD, Ehlhardt WJ.

Oncol Rep. 1998 Sep-Oct;5(5):1089-94.

PMID:
9683814
11.

Disposition and metabolism of the sulfonylurea oncolytic agent LY295501 in mouse, rat, and monkey.

Ehlhardt WJ, Woodland JM, Toth JE, Ray JE, Martin DL.

Drug Metab Dispos. 1997 Jun;25(6):701-8.

12.

Metabolism and disposition of the antifolate LY231514 in mice and dogs.

Woodland JM, Barnett CJ, Dorman DE, Gruber JM, Shih C, Spangle LA, Wilson TM, Ehlhardt WJ.

Drug Metab Dispos. 1997 Jun;25(6):693-700.

13.

Sulfonimidamide analogs of oncolytic sulfonylureas.

Toth JE, Grindey GB, Ehlhardt WJ, Ray JE, Boder GB, Bewley JR, Klingerman KK, Gates SB, Rinzel SM, Schultz RM, Weir LC, Worzalla JF.

J Med Chem. 1997 Mar 14;40(6):1018-25.

PMID:
9083492
14.

Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein.

Starling JJ, Shepard RL, Cao J, Law KL, Norman BH, Kroin JS, Ehlhardt WJ, Baughman TM, Winter MA, Bell MG, Shih C, Gruber J, Elmquist WF, Dantzig AH.

Adv Enzyme Regul. 1997;37:335-47.

PMID:
9381979
15.

Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.

Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, Starling JJ.

Cancer Res. 1996 Sep 15;56(18):4171-9.

16.

Novel acid labile COL1 trityl-linked difluoronucleoside immunoconjugates: synthesis, characterization, and biological activity.

Patel VF, Hardin JN, Mastro JM, Law KL, Zimmermann JL, Ehlhardt WJ, Woodland JM, Starling JJ.

Bioconjug Chem. 1996 Jul-Aug;7(4):497-510.

PMID:
8853464
17.
18.

Pharmacokinetics of the anticancer agent sulofenur in mice, rats, monkeys, and dogs.

Ehlhardt WJ, Sullivan HR, Wood PG, Woodland JM, Hamilton M, Hamilton C, Cornpropst D, Grindey GB, Worzalla JF, Bewley JR, et al.

J Pharm Sci. 1993 Jul;82(7):683-8.

PMID:
8360840
19.

Biotransformation of the antiviral agent 1,3,4-thiadiazol-2-ylcyanamide (LY217896) and characteristics of a mesoionic ribose metabolite.

Ehlhardt WJ, Wheeler WJ, Breau AP, Chay SH, Birch GM.

Drug Metab Dispos. 1993 Jan-Feb;21(1):162-70.

PMID:
8095212
20.

Formation of indenesulfonylureas in the metabolism of the anticancer agent sulofenur in rats, monkeys, and humans.

Ehlhardt WJ, Zimmermann JL, Ray JE, Toth JE.

Drug Metab Dispos. 1992 Nov-Dec;20(6):958-61. No abstract available.

PMID:
1362953
21.

Comparison of metabolism and toxicity to the structure of the anticancer agent sulofenur and related sulfonylureas.

Ehlhardt WJ, Woodland JM, Worzalla JF, Bewley JR, Grindey GB, Todd GC, Toth JE, Howbert JJ.

Chem Res Toxicol. 1992 Sep-Oct;5(5):667-73.

PMID:
1446007
22.
23.

Metabolism and disposition of p-chloroaniline in rat, mouse, and monkey.

Ehlhardt WJ, Howbert JJ.

Drug Metab Dispos. 1991 Mar-Apr;19(2):366-9.

PMID:
1676638
25.

Mammalian cell toxicity and bacterial mutagenicity of nitrosoimidazoles.

Ehlhardt WJ, Beaulieu BB Jr, Goldman P.

Biochem Pharmacol. 1988 Jul 1;37(13):2603-6.

PMID:
3390219
26.

Nitrosoimidazoles: highly bactericidal analogues of 5-nitroimidazole drugs.

Ehlhardt WJ, Beaulieu BB Jr, Goldman P.

J Med Chem. 1988 Feb;31(2):323-9.

PMID:
3339605
27.
28.

Formation of an amino reduction product of metronidazole in bacterial cultures: lack of bactericidal activity.

Ehlhardt WJ, Beaulieu BB Jr, Goldman P.

Biochem Pharmacol. 1987 Jan 15;36(2):259-64.

PMID:
3545214

Supplemental Content

Loading ...
Support Center